Word: hoechst
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...subsidiary Searle makes the wildly successful arthritis drug Celebrex, has been casting around for a merger partner for over a year, and now, executives say, the search is over. Monsanto will merge with Pharmacia & Upjohn, joining the ranks of other mega-merger firms like Astra-Zeneca and Rhone-Poulenc-Hoechst, to form a corporation worth about $52 billion. Why did it take so long for Monsanto to find its mate, and why was Pharmacia willing to take it on? The answers lie in Monsanto's agri-chemical division, a successful but controversial arm of the company, which is the target...
Armed with this knowledge, says Edward Keystone, director of advanced therapeutics in arthritis at Mount Sinai Hospital in Toronto, "we're targeting every element of this disease from start to finish." The new drug Arava, for example, created by the Kansas City, Mo., firm Hoechst Marion Roussel, stops white cells from reproducing. Enbrel, a genetically engineered medication from Seattle-based Immunex, works by sopping up a tumor-killing cytokine called tumor necrosis factor before it can issue its call for reinforcements. The COX-2 inhibitors target prostaglandin production, limiting pain and inflammation. And the blood-filtration device, invented at Cypress...
...Food and Drug Administration might be reluctant to green-light the drug. That's because the FDA's pressure prompted Hoechst-Marion-Roussel to pull probucol from the market two years ago: The drug lowers the body's levels of artery-protecting "good" cholesterol by 40 percent, a definite drawback...
PARIS: Bowing to boycott threats from American anti-abortion groups, European pharmaceutical giant Hoechst transferred non-U.S. patent rights to the abortion pill RU-486 to one of the doctors who invented it. Although Edouard Sakiz, who headed Roussel Uclaf, the company that lead the development of RU-486 before it was acquired by Hoechst, will market the drug worldwide through a new company, he said he will not do business in the U.S. Once the drug wins approval, it will be distributed by The Population Council, a New York-based non-profit that received the U.S. patent from...
...abortion business. "Searle has never willingly made ((Cytotec)) available for use in abortion," a company official wrote in a letter to the Wall Street Journal in February. "It is not Searle's intention or desire to become embroiled in the abortion issue." Searle's reservations echo that of Hoechst president Wolfgang Hilger, who has been open about his ethical objections...